Introduction {#S1}
============

Liver cancer is the fourth leading cause of cancer-related death worldwide and ranks sixth in terms of incidence ([@B7]; [@B63]). Among all types of primary malignant liver tumors, hepatocellular carcinoma (HCC) accounts for approximately 85--90% of all cases. The major risk factors including chronic infections by hepatitis B virus (HBV) and hepatitis C virus (HCV), aflatoxin exposure, smoking, type 2 diabetes, obesity, and so on ([@B40]; [@B7]; [@B48]). As a highly heterogeneous cancer disease, localized HCC patients often have poor prognosis with 5-year overall survival (OS) rate of 30%, and this rate drops below 5% for those with distant metastases ([@B45]). For patients at early disease stages, liver resection is the most effective treatment option, however, only less than 30% of HCC patients are eligible surgery, and among those around 70% eventually relapse within 5 years after treatment ([@B66]). Over the past few decades, despite advances in chemotherapy, targeted therapy, radiation therapy, and immunotherapy in the clinical arena, the survival of HCC patients has not significantly increased, and translational studies to understand the mechanisms and prognosis remain underwhelming to design novel therapeutic strategies ([@B65]; [@B3]; [@B36]).

Data, information, knowledge and wisdom (DIKW) model has been widely used in life in all aspects including medicine ([@B59], [@B57]; [@B16], [@B17]; [@B18], [@B19]). In recent years, genome-wide profiling has substantially advanced our understanding of the genetic landscape and driver pathways leading to HCC ([@B61]; [@B53]; [@B76]; [@B1]; [@B63]), revealing Cellular tumor antigen p53 (*TP53*), Catenin beta-1 (*CTNNB1*), Axin-1 (*AXIN1*), Telomerase reverse transcriptase (*TERT*) promoter and other key genes as driver mutations, and WNT/β-catenin, p53 cell cycle pathway, oxidative stress, PI3K/AKT/MTOR, and RAS/RAF/MAPK pathways as key signaling pathways involved in liver carcinogenesis. However, existing studies have been of limited sample size that failed to create molecular prognostic indices and also the inconsistent computational methods may have restricted the power to identify potential meaningful molecular biomarkers and new therapeutic targets. Therefore, an integrated bioinformatics study combining the most updated genomic data thus providing novel insight into the mechanisms underlying therapeutic resistance and disease progression is highly warranted.

Microarray technology has become an indispensable tool to monitor genome wide expression levels of genes in a given organism and has been successfully used to classify different types of cancer and predict clinical outcomes ([@B62]). These microarray technologies have also been applied in many studies to define global gene expression patterns in primary human HCC in an attempt to gain insight into the mechanisms of hepatocarcinogenesis ([@B13]; [@B69]; [@B23]; [@B64]; [@B26]). In the present study, we selected four independent datasets consisting a total of 320 HCC cases and 270 cases of normal liver tissues in the Gene Expression Omnibus (GEO) database to identify reliable markers and pathway alterations linked with the pathogenesis of HCC cases ([@B70]; [@B41]; [@B50]). We identified 89 differential expression genes (DEGs) including 31 up-regulated genes and 58 down-regulated genes. Gene ontology (GO) analysis revealed cellular response to zinc ion in biological process (BP) group, collagen trimer in the cellular component (CC) group, and extracellular matrix (ECM) structural constituent conferring tensile strength in the molecular function (MF) group. Further pathway enrichment analysis revealed that enrichment in protein digestion and absorption, mineral absorption, propanoate metabolism, and ECM-receptor interaction. Finally, the top five hub genes osteopontin (*SPP1*), Collagen alpha-2(I) chain (*COL1A2*), Insulin-like growth factor I (*IGF1*), lipoprotein A (*LPA*), and Galectin-3 (*LGALS3*) were identified from the protein--protein interaction (PPI) network and those highly altered genes were validated by western blot assay and Immunohistochemistry (IHC) analysis and found to be associated with clinical outcome of HCC patients.

Materials and Methods {#S2}
=====================

Data Source and Identification of DEGs {#S2.SS1}
--------------------------------------

Microarrays data were obtained from the Oncomine 4.5 database^[1](#footnote1){ref-type="fn"}^ contains 715 datasets and 86,733 samples. Of which, we filtered four datasets comprising Mas liver (GSE14323, containing 19 liver tissues and 38 HCCs), Roessler liver (GSE14520 based on GPL571 platform, containing 21 liver tissues and 22 HCCs), Roessler liver 2 (GSE14520 based on GPL3921 platform, containing 220 liver tissues and 225 HCCs), and Wurmbach liver (GSE6764, containing 10 liver tissues and 35 HCCs) after using the following criteria: (a) Analysis type: cancer vs. normal analysis; (b) Cancer type: hepatocellular carcinoma; (c) Data type: mRNA; (d) Sample type: clinical specimen; (e) Microarray platform: Human Genome U133A, U133A 2.0, or U133 Plus 2.0. A total of 270 cases of normal liver tissues and 320 cases of HCCs were included in the integrated analysis. To analyze the DEGs between HCC and normal liver tissues, the data were then processed on GEO2R website^[2](#footnote2){ref-type="fn"}^. The differentially expressed genes were identified using limma R package at a cutoff \| logFC\| \> 1 and adjusted *p* value \< 0.05 (Benjamini & Hochberg).

GO and Pathways Enrichment Analysis {#S2.SS2}
-----------------------------------

The annotation function of GO analysis is comprised of three categories: BP, CC, and MF. Kyoto Encyclopedia of Genes and Genomes (KEGG) is a database resource for understanding high-level functions and utilities of the genes or proteins ([@B28]; [@B29], [@B30]). GO analysis and KEGG pathway enrichment analysis of candidate DEGs were performed using the R package "clusterProfiler." Reactome^[3](#footnote3){ref-type="fn"}^ was also used for pathway enrichment analysis ([@B20]). Adjusted *p*-value less than 0.05 was considered as the cut-off criterion for both GO analysis and pathway enrichment analysis.

PPI Network and Modular Analysis {#S2.SS3}
--------------------------------

Protein--protein interaction network was constructed to determine the importance of these DEGs by comparing the interactions between different DEGs. STRING database^[4](#footnote4){ref-type="fn"}^ and Cytoscape software (3.7.2 version) were applied to construct and visualize the PPI networks ([@B60]), followed by Molecular Complex Detection (MCODE) plug-in in Cytoscape for selecting significant modules of hub genes from the PPI network ([@B4]), with the following criteria: degree cutoff (number of connections with other nodes) ≥ 2, node score cutoff (the most influential parameter for cluster size) ≥ 2, K-core (This parameter filters out clusters that do not contain a maximally inter-connected sub-cluster of at least k degrees. For example, a triangle including three nodes and three edges is a two-core representing two connections per node. Two nodes with two edges between them meet the two-core rule as well) ≥ 2 and max depth (this parameter limits the distance from the seed node within which MCODE can search for cluster members) = 100. KEGG pathway enrichment analysis of the modules was carried out using the online DAVID database^[5](#footnote5){ref-type="fn"}^ ([@B24]).

Hub Gene Selection and Prognostic Analysis {#S2.SS4}
------------------------------------------

Hub genes were selected based on comparison of top 10 genes ranked by degree and betweenness centrality Network of hub genes. Their co-expressed genes were then analyzed using cBioPortal online platform^[6](#footnote6){ref-type="fn"}^ ([@B22]). Genetic alterations of these hub genes were explored and compared using the cBioPortal database. Biological process analysis of hub genes was then performed and visualized using plug-in Biological Networks Gene Oncology tool (BiNGO) app in Cytoscape software ([@B38]). Stage-related information analysis based on gene expression was performed in UALCAN^[7](#footnote7){ref-type="fn"}^, a comprehensive web resource for analyzing omics data ([@B9]). Disease-free survival (DFS) is a concept used to describe the period after a successful treatment of cancer. OS means the length of time from either the date of diagnosis or the start of treatment for HCC. DFS and OS are both measured to see how well a new treatment works. DFS and OS analysis associated with these hub genes were performed using the Kaplan--Meier Plotter online database^[8](#footnote8){ref-type="fn"}^.

Cell Lines and Cell Culture {#S2.SS5}
---------------------------

Hepatocellular carcinoma cell lines Hep3B and HepG2 and human normal liver cell line L02 were obtained from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. All of these cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) (catalog number 10569010, Gibco) containing 10% (v/v) fetal bovine serum (FBS) (catalog number 10091148, Gibco) supplemented with 1% (v/v) penicillin streptomycin solution (catalog number SV30010, Hyclone) (containing 100 U/ml penicillin and 100 μg/ml streptomycin) in a humidified incubator at 37°C with 5% CO~2~.

Protein Preparation and Western Blot Analysis {#S2.SS6}
---------------------------------------------

Briefly, HCC cells were lysed with cold M-PER lysate buffer (catalog number 78501, Roche) \[containing 1 × protease inhibitors (catalog number 11836153001, Roche) and phosphatase inhibitor cocktail (catalog number 78420, Roche)\] and centrifuged at 4°C for 10 min. The protein concentrations of collected supernatants were determined by the BCA protein assay kit (catalog number P0011, Beyotime). Equal amounts of total proteins were separated in 10 or 12% SDS-PAGE and transblotted onto the 0.45 μm PVDF membranes (catalog number 1620177, BIO-RAD). The membranes were blocked in 5% fat-free milk in TBST (150 mM NaCl, 50 mM Tris, pH 7.2) for 1 h at room temperature and subsequently incubated with corresponding primary antibodies as following: anti-SPP1 (catalog number ab8448, Abcam, 1:1000), anti-COL1A2 (catalog number 66761-1-lg, Proteintech, 1:1000), anti-IGF1 (catalog number ab9572, Abcam, 1:1000), anti-LGALS3 (catalog number ab209344, Abcam, 1:1000), anti-GADPH (catalog number 10494-1-AP, Proteintech, 1:10000), and anti-β-Tubulin (catalog number T0023, Affinity, 1:20000) at 4°C overnight, followed by incubation with a donkey anti-mouse (catalog number C61116-02, LI-COR) or goat anti-rabbit (catalog number C80118-05, LI-COR) secondary antibody for 1 h at room temperature. Then membranes were scanned using the Odyssey infrared imaging system (LI-COR) and the images were captured. The gray levels of the bands were determined by Image J software. The expression of proteins was normalized using the GADPH or β-Tubulin values. The assay was performed three independent times.

Patient Samples {#S2.SS7}
---------------

This study was approved by Cancer Hospital of the University of Chinese Academy of Sciences; Zhejiang Cancer Hospital. Twenty formalin-fixed, paraffin-embedded (FFPE) HCC tissues and corresponding adjacent non-cancerous tissues were collected from the Department of Abdominal Surgery, Zhejiang Cancer Hospital. All FFPE HCC tissues were screened by two pathologists independently to confirm the diagnosis of HCC. The most representative tumor and non-cancerous tissues were selected for immunohistochemistry analysis.

IHC Analysis {#S2.SS8}
------------

Neutral 10% buffered formalin-fixed tissue specimens were embedded in paraffin wax and then sliced to 4-micron thick sections by a microtome. In brief, the tissue slices were firstly deparaffinized, followed by rehydration and a 10-min boiling in 10 mmol/L citrate buffer (pH = 6.4) for antigen retrieval. Then, the sections were treated in methanol containing 3% H~2~O~2~ for 20 min to inhibit the endogenous tissue peroxidase activity. After being blocked with 1% bovine serum albumin (BSA) at 37°C for 30 min, IHC staining was carried out for the protein expression of SPP1, COL1A2, IGF1, and LGALS3 using specific primary antibodies at 4°C overnight, followed by staining with species-specific secondary antibodies labeled with horseradish peroxidase (HRP). The slides were developed in diaminobenzidine (DAB) and counter-stained with hematoxylin. Then images of the sections were photographed using an Olympus microscope (Olympus Life Science). The clinical specimen data of LPA were obtained from The Human Protein Atlas database^[9](#footnote9){ref-type="fn"}^.

Statistical Analysis {#S2.SS9}
--------------------

Statistical analysis was performed using GraphPad Prism software (version 8.0.1) and R software (version 3.4.2^[10](#footnote10){ref-type="fn"}^). *p*-value \< 0.05 was considered statistically significant. The column diagram was graphed with GraphPad Prism software (version 8.0.1).

Results {#S3}
=======

Data Source and Analysis {#S3.SS1}
------------------------

A total of 603, 1,238, 1,095, and 1,722 DEGs have been extracted from the four independent expression datasets Mas liver, Roessler liver, Roessler liver 2, and Wurmbach liver, respectively ([Figures 1A--D](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}, and [Supplementary Tables S1](#TS1){ref-type="supplementary-material"}, [S2](#TS2){ref-type="supplementary-material"}). The comparison of all genes from these datasets identified 89 consistently and significantly dysregulated genes, including 31 up-regulated genes and 58 down-regulated genes in HCC compared to normal liver tissues ([Figures 1E,F](#F1){ref-type="fig"} and [Supplementary Table S3](#TS3){ref-type="supplementary-material"}). Notably, several genes such as Glypican-3 (*GPC3*) ([@B70]) and *SPP1* ([@B50]) have been reported previously, proving the feasibility of the method.

![The DEGs screened from four independent datasets. Up-regulated DEGs (red-colored dots) and down-regulated (blue-colored dots) DEGs are selected with \[logFC\] \> 1 and adjust *p*-value \< 0.05 from the mRNA expression profiling sets **(A)** Mas liver, **(B)** Wurmbach liver, **(C)** Roessler liver, and **(D)** Roessler liver 2. Venn diagram showed **(E)** 31 consistently up-regulated DEGs and **(F)** 58 consistently down-regulated DEGs in four datasets.](fgene-11-00814-g001){#F1}

###### 

Details of the four HCC datasets.

  **Datasets**       **GSE**                      **Tumor**   **Normal**   **References**
  ------------------ ---------------------------- ----------- ------------ ----------------
  Mas liver          GSE14323                     38          19           [@B41]
  Roessler liver     GSE14520(GPL571 platform)    22          21           [@B50]
  Roessler liver 2   GSE14520(GPL3921 platform)   225         220          [@B50]
  Wurmbach liver     GSE6764                      35          10           [@B70]

HCC, Hepatocellular carcinoma.

GO Analysis of DEGs in HCC {#S3.SS2}
--------------------------

The functional characteristics of these 89 DEGs were explored using GO analysis and were grouped into BP, cell component and MF ([Figure 2A](#F2){ref-type="fig"}). Overall, cellular response to zinc ion covering five genes was found to be the dominant BP. Collagen trimer covering seven genes was found to be the top CC. ECM structural constituent conferring tensile strength covering five genes was the top MF. As shown in [Table 2](#T2){ref-type="table"}, in the BP group, up-regulated genes were mainly enriched in ECM organization, epithelial tube morphogenesis, and positive regulation of leukocyte migration while down-regulated genes were mainly enriched in cellular response to zinc ion and humoral immune response. In the CC group, up-regulated genes were mainly enriched in collagen-containing ECM and ECM components while down-regulated genes mainly enriched in blood microparticle. In the MF group, up-regulated genes were mainly enriched in ECM structural constituents while down-regulated genes were mainly enriched in pattern binding. Taken together, these data suggest that those identified DEGs are mainly enriched in ECM-related items affecting the BP of negative regulation of growth, humoral immune response and so on.

![GO and KEGG pathway enrichment analysis **(A)** GO analysis of all DEGs. The most enriched GO terms are listed in the diagram. **(B)** KEGG pathway analysis of all DEGs. The most enriched KEGG pathways are shown in the picture.](fgene-11-00814-g002){#F2}

###### 

Significantly enriched GO terms of DEGs associated with HCC with adjust *p*-value \< 0.01.

  **Expression**   **Category**   **Term**                                                                             **Count**   ***p*-value**   **Adj *p*-value**
  ---------------- -------------- ------------------------------------------------------------------------------------ ----------- --------------- -------------------
  Up-regulated     CC             GO:0062023∼collagen-containing extracellular matrix                                  9           \<0.001         \<0.001
                   CC             GO:0044420∼extracellular matrix component                                            5           \<0.001         \<0.001
                   CC             GO:0098644∼complex of collagen trimers                                               4           \<0.001         \<0.001
                   CC             GO:0031012∼extracellular matrix                                                      9           \<0.001         \<0.001
                   CC             GO:0005581∼collagen trimer                                                           5           \<0.001         \<0.001
                   CC             GO:0005788∼endoplasmic reticulum lumen                                               7           \<0.001         \<0.001
                   CC             GO:0005604∼basement membrane                                                         4           \<0.001         \<0.001
                   CC             GO:0042470∼melanosome                                                                4           \<0.001         \<0.001
                   CC             GO:0048770∼pigment granule                                                           4           \<0.001         \<0.001
                   CC             GO:0005583∼fibrillar collagen trimer                                                 2           \<0.001         0.001
                   CC             GO:0098643∼banded collagen fibril                                                    2           \<0.001         0.001
                   MF             GO:0030020∼extracellular matrix structural constituent conferring tensile strength   5           \<0.001         \<0.001
                   MF             GO:0005201∼extracellular matrix structural constituent                               5           \<0.001         0.001
                   MF             GO:0048407∼platelet-derived growth factor binding                                    2           \<0.001         0.008
  Down-regulated   BP             GO:0071294∼cellular response to zinc ion                                             5           \<0.001         \<0.001
                   BP             GO:0010043∼response to zinc ion                                                      6           \<0.001         \<0.001
                   BP             GO:0006956∼complement activation                                                     7           \<0.001         \<0.001
                   BP             GO:0072376∼protein activation cascade                                                7           \<0.001         \<0.001
                   BP             GO:0071276∼cellular response to cadmium ion                                          4           \<0.001         0.001
                   BP             GO:0001867∼complement activation, lectin pathway                                     3           \<0.001         0.001
                   BP             GO:0006959∼humoral immune response                                                   7           \<0.001         0.003
                   BP             GO:0046686∼response to cadmium ion                                                   4           \<0.001         0.004
                   BP             GO:0010460∼positive regulation of heart rate                                         3           \<0.001         0.008
                   BP             GO:0010038∼response to metal ion                                                     7           \<0.001         0.008
                   CC             GO:0072562∼blood microparticle                                                       5           \<0.001         0.008
                   MF             GO:0001871∼pattern binding                                                           3           \<0.001         0.004
                   MF             GO:0030247∼polysaccharide binding                                                    3           \<0.001         0.004
                   MF             GO:1901681∼sulfur compound binding                                                   6           \<0.001         0.005
                   MF             GO:0050662∼coenzyme binding                                                          6           \<0.001         0.008

BP, biological process; CC, cellular component; MF, molecular function.

Signaling Pathway Enrichment Analysis {#S3.SS3}
-------------------------------------

To understand the biological changes during HCC pathogenesis, we performed pathway enrichment analysis using KEGG and Reactome. KEGG pathways enrichment analysis showed that those candidate DEGs were primarily enriched in protein digestion and absorption, mineral absorption, and ECM-receptor interaction ([Figure 2B](#F2){ref-type="fig"}). Among them, up-regulated genes were mainly enriched in protein digestion and absorption and ECM-receptor interaction while down-regulated genes were mainly enriched in mineral absorption and metabolic pathways ([Table 3](#T3){ref-type="table"}). Furthermore, Reactome pathway enrichment analysis showed that the DEGs were enriched in collagen chain trimerization, collagen degradation, metallothioneins bind metals, and response to metal ions ([Supplementary Table S4](#TS4){ref-type="supplementary-material"}). Among them, up-regulated genes were primarily enriched in collagen chain trimerization, assembly of collagen fibrils and other multimeric structures and collagen degradation, while down-regulated genes were enriched in metallothioneins bind metals, response to metal ions and ficolins bind to repetitive carbohydrate structures on the target cell surface ([Table 4](#T4){ref-type="table"}).

###### 

KEGG pathway enrichment analysis of DEGs in HCC.

  **Expression**   **KEGG Term**                                                     **Count**   ***p*-value**   **Adj *p*-value**
  ---------------- ----------------------------------------------------------------- ----------- --------------- -------------------
  Up-regulated     hsa04974∼Protein digestion and absorption                         6           \<0.001         \<0.001
                   hsa04512∼ECM-receptor interaction                                 4           \<0.001         0.003
                   hsa04964∼Proximal tubule bicarbonate reclamation                  2           0.002           0.028
                   hsa04510∼Focal adhesion                                           4           0.002           0.028
                   hsa04151∼*PI3K/Akt* signaling pathway                             5           0.002           0.028
                   hsa04933∼*AGE-RAGE* signaling pathway in diabetic complications   3           0.003           0.028
                   hsa05146∼Amoebiasis                                               3           0.003           0.028
                   hsa04926∼Relaxin signaling pathway                                3           0.005           0.048
  Down-regulated   hsa04978∼Mineral absorption                                       5           \<0.001         0.001
                   hsa00640∼Propanoate metabolism                                    3           0.001           0.025

###### 

Pathways enriched in Reactome analysis of DEGs in HCC (Adj *p*-value \< 0.01).

  **Expression**   **Pathway name**                                                                                      **Count**   ***p*-value**   **Adj *p*-value**
  ---------------- ----------------------------------------------------------------------------------------------------- ----------- --------------- -------------------
  Up-regulated     R-HSA-8948216∼Collagen chain trimerization                                                            5           \<0.001         \<0.001
                   R-HSA-2022090∼Assembly of collagen fibrils and other multimeric structures                            5           \<0.001         \<0.001
                   R-HSA-1442490∼Collagen degradation                                                                    5           \<0.001         \<0.001
                   R-HSA-1650814∼Collagen biosynthesis and modifying enzymes                                             5           \<0.001         \<0.001
                   R-HSA-216083∼Integrin cell surface interactions                                                       6           \<0.001         \<0.001
                   R-HSA-1474228∼Degradation of the extracellular matrix                                                 6           \<0.001         \<0.001
                   R-HSA-1474290∼Collagen formation                                                                      5           \<0.001         \<0.001
                   R-HSA-3000171∼Non-integrin membrane-ECM interactions                                                  4           \<0.001         \<0.001
                   R-HSA-1474244∼Extracellular matrix organization                                                       6           \<0.001         \<0.001
                   R-HSA-2214320∼Anchoring fibril formation                                                              3           \<0.001         0.001
                   R-HSA-422475∼Axon guidance                                                                            8           \<0.001         0.002
                   R-HSA-8985801∼Regulation of cortical dendrite branching                                               1           \<0.001         0.002
                   R-HSA-2243919∼Crosslinking of collagen fibrils                                                        3           \<0.001         0.002
                   R-HSA-186797∼Signaling by *PDGF*                                                                      4           \<0.001         0.003
                   R-HSA-8941333∼*RUNX2* regulates genes involved in differentiation of myeloid cells                    1           \<0.001         0.004
                   R-HSA-3000178∼ECM proteoglycans                                                                       4           \<0.001         0.004
                   R-HSA-69205∼G1/S-Specific Transcription                                                               2           0.001           0.009
                   R-HSA-3769402∼Deactivation of the beta-catenin transactivating complex                                3           0.001           0.009
                   R-HSA-419037∼*NCAM1* interactions                                                                     3           0.001           0.009
                   R-HSA-8949275∼*RUNX3* Regulates Immune Response and Cell Migration                                    1           0.001           0.009
                   R-HSA-8939246∼*RUNX1* regulates transcription of genes involved in differentiation of myeloid cells   1           0.001           0.010
                   R-HSA-3000480∼Scavenging by Class A Receptors                                                         3           0.001           0.010
  Down-regulated   R-HSA-5661231∼Metallothioneins bind metals                                                            5           \<0.001         \<0.001
                   R-HSA-5660526∼Response to metal ions                                                                  5           \<0.001         \<0.001
                   R-HSA-2855086∼Ficolins bind to repetitive carbohydrate structures on the target cell surface          3           \<0.001         \<0.001
                   R-HSA-166662∼Lectin pathway of complement activation                                                  3           \<0.001         \<0.001
                   R-HSA-166658∼Complement cascade                                                                       6           \<0.001         0.003

Key Candidate Genes and Pathways Identified by DEGs PPI and Modular Analysis {#S3.SS4}
----------------------------------------------------------------------------

In order to identify key candidate genes, 63 DEGs (24 up-regulated genes and 39 down-regulated genes) were filtered into the PPI network complex, including 63 nodes and 78 edges. Among the 63 nodes, only genes ranking in top 10 of both degrees (the number of interactions of each node) and betweenness centrality (degree of impact on interactions between other nodes in the network) parameters were recognized as hub genes. Finally, five genes *SPP1*, *COL1A2*, *IGF1*, *LGALS3*, and *LPA* were selected ([Figure 3A](#F3){ref-type="fig"} and [Table 5](#T5){ref-type="table"}). Utilizing MCODE plug-in app in cytoscape, two modules were applied for further KEGG pathway enrichment analysis. Module 1 consisted of 5 nodes and 10 edges with genes enriched in protein digestion and absorption, ECM-receptor interaction, amoebiasis and focal adhesion. Module 2 consisted of five nodes and nine edges with the genes mainly enriched in mineral absorption ([Figures 3B,C](#F3){ref-type="fig"} and [Supplementary Table S5](#TS5){ref-type="supplementary-material"}).

![The protein--protein interaction (PPI) of DEGs exported from STRING is visualized using Cytoscape software. Up-regulated DEGs are shown in red while down-regulated DEGs are shown in green dots. **(A)** 63 nodes and 78 edges are displayed. Larger node sizes correspond to higher degrees of DEGs. Label font sizes are shown in black from small to large according to the Betweenness centrality (from low to high). The hub genes we selected are emphasized and shown in the shape of round rectangles. **(B,C)** Module 1, module 2 and their related specifications determined by MCODE plug-in app in Cytoscape software. Circles represent genes and the lines between genes indicate the gene-encoded PPIs.](fgene-11-00814-g003){#F3}

###### 

Top 10 most degree values and betweenness centrality hub genes between HCC and normal samples.

  **Genes**      **Expression**   **Betweenness centrality**   **Genes**      **Expression**   **Degree**
  -------------- ---------------- ---------------------------- -------------- ---------------- ------------
  *CYP2C19*      Down             1                            ***SPP1***     Up               8
  *STEAP3*       Down             1                            ***COL1A2***   Up               8
  *TYMS*         Up               0.83333333                   ***IGF1***     Down             6
  ***SPP1***     Up               0.50873984                   *SOX9*         Up               5
  *GMNN*         Up               0.5                          *COL4A2*       Up               5
  ***LPA***      Down             0.30264228                   ***LPA***      Down             4
  ***IGF1***     Down             0.29329268                   ***LGALS3***   Up               4
  ***LGALS3***   Up               0.24573171                   *C9*           Down             4
  ***COL1A2***   Up               0.19756098                   *SERPINA10*    Down             4
  *MDK*          Up               0.1804878                    *ROBO1*        Up               4

Genes were ranked by betweenness centrality and degree, respectively. The genes in red are the shared genes with the two analysis methods.

Hub Genes and Associations With Clinical Outcome {#S3.SS5}
------------------------------------------------

The network of hub genes constructed by cBioPortal contained 55 nodes, including five query genes (five hub genes) and the 50 most frequently altered neighbor genes ([Figure 4A](#F4){ref-type="fig"}). After visualizing BP using BiNGO in Cytoscape software ([Supplementary Figure S1](#FS1){ref-type="supplementary-material"}), genetic alteration analysis of five hub genes in TCGA HCC patients was performed in the cBioPortal database. The hub genes *SPP1*, *IGF1*, *LGALS3*, *LPA*, and *COL1A2* were altered in 4, 5, 5, 7, and 8% in a total population of HCC patients respectively, without significantly discrepancy in both sexes ([Figure 4B](#F4){ref-type="fig"}). TCGA data analysis showed that *SPP1*, *COL1A2*, and LGALS3 are more highly expressed in HCC regardless of stages compared with normal tissues, while *IGF1* and *LPA* were low expressed ([Figure 5](#F5){ref-type="fig"}). Further western blot analysis showed that the protein expression levels of *SPP1*, *COL1A2*, and *LGALS3* were highly expressed in HCC cell lines while IGF1 was down-regulated in HCC cell lines ([Figure 6A](#F6){ref-type="fig"}). IHC analysis of HCC patient tissues showed similar results as western blot analysis ([Figure 6B](#F6){ref-type="fig"}). The online human protein atlas showed the LPA protein expression was higher in normal liver tissues than in HCC tissues. For the identified five top hub genes, HCC patients with high expressions of *COL1A2*, *IGF1*, and *LPA* as well as low expression of *SPP1* were found to be associated with the improved DFS (*p* = 0.0017, *p* = 0.0021, *p* = 0.0058, and *p* = 7e^--04^, respectively) ([Figure 7](#F7){ref-type="fig"}). High expression of *SPP1* and *LGALS3* were linked with the disfavored OS (*p* = 3.5e^--06^ and *p* = 0.014, respectively) ([Figures 8A,D](#F8){ref-type="fig"}), while high expression of *IGF1* and *LPA* were associated with improved OS (*p* = 0.0013 and *p* = 0.00038, respectively) ([Figures 8C,E](#F8){ref-type="fig"}). However, expression of *COL1A2* didn't show a significant correlation with clinical outcome (*p* = 0.21) ([Figure 8B](#F8){ref-type="fig"}).

![Analysis of hub genes. **(A)** Hub genes and their co-expressed genes are analyzed using cBioPortal. Hub genes are represented with a thick border. Darker red indicates increased frequency of alteration in HCC. The blue connection indicates that the first protein controlled a reaction that changes the state of the second protein; the red connection suggests that the proteins belongs to members of the same complex. The green arrows represent "Controls expression of." The gray arrows represent "In complex with." **(B)** Genetic alteration analysis toward these five genes, overall survivals are also shown.](fgene-11-00814-g004){#F4}

![Expression of hub genes in different HCC stages in TGCA database: **(A)** *SPP1*, **(B)** *COL1A2*, **(C)** *IGF1*, **(D)** *LGALS3*, and **(E)** *LPA*. *SPP1*, *COL1A2*, and *LGAlS3* are overexpressed in HCC tissues while *IGF1* and *LPA* are downregulated in HCC tissues compared to the control.](fgene-11-00814-g005){#F5}

![Protein expression levels of these hub genes in normal liver cell line L02 and HCC cell lines Hep3B and HepG2 were examined by western blot analysis. The bands were analyzed and normalized using the GADPH or β-Tubulin values and processed by Image J software. **(A)** The representative cases of HCC patient tissues were detected by **(B)** Immunohistochemistry. The western blot and Immunohistochemistry results showed that SPP1, COL1A2, and LGALS3 are overexpressed in HCC samples while IGF1 is downregulated in HCC samples.](fgene-11-00814-g006){#F6}

![Disease-free survival (DFS) analysis of **(A)** *SPP1*, **(B)** *COL1A2*, **(C)** *IGF1*, **(D)** *LGALS3*, and **(E)** *LPA* in HCC patients. HCC patients with high expressions of *COL1A2*, *IGF1*, and *LPA* as well as low expression of *SPP1* were found to be associated with the improved DFS (*p* = 0.0017, *p* = 0.0021, *p* = 0.0058, and *p* = 7e^--04^, respectively).](fgene-11-00814-g007){#F7}

![Overall survival (OS) analysis of **(A)** *SPP1*, **(B)** *COL1A2*, **(C)** *IGF1*, **(D)** *LGALS3*, and **(E)** *LPA* in HCC patients. High expression of *SPP1* and *LGALS3* were linked with the disfavored OS (*p* = 3.5e^--06^ and *p* = 0.014, respectively) **(A,D)**, while high expression of *IGF1* and *LPA* were associated with improved OS (*p* = 0.0013 and *p* = 0.00038, respectively).](fgene-11-00814-g008){#F8}

Discussion {#S4}
==========

Hepatocellular carcinoma remains an aggressive form of cancer worldwide with high incidence and morbidity. Therefore, substantial efforts have been made to unveil mutational processes, pathogenesis and possible mechanisms underlying treatment resistance in order to expand the therapeutic landscape of this disease ([@B36]; [@B12]). However, most of these studies were based on single institutions with limited sample size, restricting the power to identify potential meaningful therapeutic targets ([@B72]; [@B35]; [@B74]). Different HCC studies showed different results for different datasets chosen. In previous studies, some only chose one dataset and others chose datasets without performing explicit infiltration, leading to totally different outcome ([@B72]; [@B35]; [@B74]). Here, we conducted an integrative analysis from four microarray datasets of HCC screened in Oncomine database and downloaded in GEO database to describe key candidate genes and pathways associated with clinical outcome in HCC patients.

In the present study, a total of 89 DEGs were identified between HCC and normal tissues, including 31 up-regulated genes and 58 down-regulated genes. Up-regulated DEGs of HCC were found to be enriched in GO categories such as epithelial tube morphogenesis, ECM organization, and positive regulation of leukocyte migration, and dysregulation of these processes have been found to contribute to several pathological conditions including cancer and may lead to disfavored clinical outcomes ([@B46]; [@B5]). While down-regulated genes were associated with GO categories such as cellular response to zinc ion where members of metallothionein family (*MT1M*, *MT1H*, *MT1X*, *MT1G*, and *MT1F*) play important roles in carcinogenesis of various cancer types ([@B54]). KEGG pathway enrichment analysis demonstrated that up-regulated genes were significantly enriched in protein digestion and absorption, ECM-receptor interaction and PI3K/Akt signaling pathway while down-regulated genes were enriched in mineral absorption and metabolic pathways, and all those are significant pathways in various cancer types been reported previously ([@B6]; [@B15]; [@B67]; [@B55]). Intriguingly, a host of altered genes were found to be associated with ECM related pathways. The ECM, an extensive part of the microenvironment in all tissues, providing a physical scaffold for its surrounding cells, bind growth factors and regulate cell behavior, plays a vital part in tumor progression ([@B27]; [@B42]).

We also constructed PPI network and identified five hub genes *SPP1*, *COL1A2*, *IGF1*, *LPA*, and *LGALS3* as key candidate genes potentially linked with pathogenesis of HCC. Their co-expressed genes were then analyzed using cBioPortal online platform. The results contained five query genes and the 50 most frequently altered neighbor genes. Among the five hub genes, *SPP1*, *COL1A2*, *IGF1*, and *LGALS3* and their co-expressed genes constructed a network. *LPA* and its co-expressed genes were isolated from the main network and didn't have directly interaction with it. That's why only four out of five hub genes contained in [Figure 4A](#F4){ref-type="fig"}. Both SPP1 and COL1A2 are members belonging to PI3K/Akt signaling pathway and ECM-receptor interaction pathway regulating cell growth ([@B21]) and drug resistance ([@B73]). SPP1, also known as osteopontin, has been reported to have the capability of regulating cell behaviors ([@B51]). Previous data also showed that targeting SPP1 could inhibit gastric cancer cell epithelial--mesenchymal transition through inhibition of the PI3K/AKT signaling pathway ([@B58]). In lung adenocarcinoma, SPP1 was found to up-regulate PD-L1 and subsequently facilitated the escape of immunity ([@B75]). These studies demonstrated that SPP1 was highly associated with the cancer invasion and progression, suggesting its potential to serve as a biomarker and target for the diagnosis and treatment of HCC. COL1A2, a member of group I collagen family, has once been reported as a target of Let-7g thus inhibiting cell migration in HCC ([@B25]) and gastric cancer cell proliferation ([@B2]). In 2018, a study found that the silencing of *COL1A2* could inhibit the proliferation, migration, and invasion of gastric cancer through regulating PI3K/AKT signaling pathway, revealing the potency of COL1A2 in HCC ([@B2]). IGF1, insulin-like growth factor 1, has the capability of maintaining the stemness in HCC, and its role of serving as an anticancer target has been confirmed by several studies ([@B31], [@B32]; [@B10]; [@B8]). IGF1 and IGF2 comprise of the IGF family, contributing largely to the activation of the PI3K/Akt signaling pathway, which was also found dysregulated by the KEGG analysis, thus enhancing the cancerogenesis of HCC ([@B33]). LPA is lipoprotein A, a special kind of low-density lipoprotein, has shown the evidence of causing inflammation and regulating HCC cell proliferation ([@B49]; [@B71]). Patients with HCC showed a statistically significant serum LPA level higher than the healthy subjects, indicating its important role in HCC patients ([@B39]). *LGALS3*, which encodes the Galectin-3 protein, is regarded as a guardian of the tumor microenvironment ([@B52]). Recent studies have shown that *LGALS3* is tightly associated with several malignancies such as Hodgkin's lymphoma ([@B34]), acute myeloid leukemia ([@B11]), and HCC ([@B56]). More importantly, *LGALS3* could increase the metastatic potential of breast cancer, might accounting for the metastatic potential of HCC ([@B47]). Through validation in western blot and IHC assays, we found that the protein expression of these five hub genes was in accordance with their mRNA expression in HCC patient tissues. Strikingly, LPA has not been tested by western blot and IHC assays due to its large molecular weight of 501 kDa, exerting huge difficulty in performing these assays. Previous studies have shown that these genes are implicated in the tumorigenesis and transformation ([@B43]; [@B44]; [@B68]; [@B14]; [@B37]). In our study, correlations of *SPP1*, *COL1A2*, *IGF1*, *LPA*, and *LGALS3* with patient prognosis highlight the importance of these five genes as potential biomarkers to stratify HCC patients as well as potential therapeutic targets, but concrete roles of these genes need further investigation. In the future studies, we will develop knockdown and overexpression HCC cell lines and mouse models of these five hub genes to demonstrate their importance in the progression of HCC *in vitro* and *in vivo*.

Taken together, this study integrated four datasets to screen for reliable and accurate biomarkers of HCC and demonstrated that several pathways are altered. Several hub genes with the expression levels have significantly associated with clinical outcome in HCC patients. Further functional study on the mechanisms of those genes leading to HCC is under way.
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